Preliminary results from the second generation tau tracer [18F]PI-2620 showed different and specific uptake patterns in AD and PSP, with no off-target binding, indicating its potential to aid differential diagnosis (Mueller et al. 2017; Barret et al. 2017). Here, MAPT is linked to supranuclear palsy, progressive, 1.